Our results suggested that the QX1 formula may constitute a novel therapeutic strategy for suppressing the activity of CaMKII, TLR4/NF-κB, and MAPK pathways, but promoting the activation of AKT, thereby decreasing the release of downstream inflammatory cytokines and thus controlling cytokine storm and regulating immune balance in sepsis. The gene discussed is AKT1; the disease is Sepsis.